Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) Net Income towards Common Stockholders: 2018-2024

Historic Net Income towards Common Stockholders for Silence Therapeutics (SLN) over the last 7 years, with Dec 2024 value amounting to -$45.3 million.

  • Silence Therapeutics' Net Income towards Common Stockholders rose 41.04% to -$21.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.5 million, marking a year-over-year increase of 15.29%. This contributed to the annual value of -$45.3 million for FY2024, which is 16.45% up from last year.
  • Per Silence Therapeutics' latest filing, its Net Income towards Common Stockholders stood at -$45.3 million for FY2024, which was up 16.45% from -$54.2 million recorded in FY2023.
  • Silence Therapeutics' 5-year Net Income towards Common Stockholders high stood at -$41.7 million for FY2020, and its period low was -$54.2 million during FY2023.
  • In the last 3 years, Silence Therapeutics' Net Income towards Common Stockholders had a median value of -$50.1 million in 2022 and averaged -$49.9 million.
  • In the last 5 years, Silence Therapeutics' Net Income towards Common Stockholders slumped by 66.94% in 2020 and then increased by 16.45% in 2024.
  • Yearly analysis of 5 years shows Silence Therapeutics' Net Income towards Common Stockholders stood at -$41.7 million in 2020, then fell by 29.89% to -$54.2 million in 2021, then rose by 7.54% to -$50.1 million in 2022, then dropped by 8.19% to -$54.2 million in 2023, then grew by 16.45% to -$45.3 million in 2024.